Related Experiment Videos
Rash in patients receiving ticlopidine after intracoronary stent placement
1Department of Clinical Pharmacy, School of Pharmacy, West Virginia University, Morgantown 26506, USA.
Insights
Ticlopidine rash after coronary stent placement may be underreported. A review found approximately 7% of patients experienced rash, higher than previously published rates.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Medicine
Background:
- Intracoronary stents are used in nearly half of nonsurgical coronary artery procedures.
- Antiplatelet therapy, including ticlopidine and aspirin, is crucial to prevent stent thrombosis.
- Ticlopidine is associated with cutaneous adverse reactions, but rash frequency post-stent placement may be underestimated.
Purpose of the Study:
- To investigate the actual frequency of cutaneous rash in patients receiving ticlopidine after intracoronary stent placement.
- To compare observed rash rates with previously reported frequencies in the literature.
Main Methods:
- Retrospective chart review of patients undergoing intracoronary stent procedures.
- Data collection included rash occurrence, severity, treatment, patient demographics, and concomitant medications.
- Analysis focused on identifying factors associated with rash development.
Main Results:
- The study identified a rash frequency of approximately 7% in patients treated with ticlopidine post-stent placement.
- This observed rate is significantly higher than the 0.8-1.6% reported in prior studies.
- Data on rash severity, treatment, and predisposing factors were collected.
Conclusions:
- The frequency of ticlopidine-induced rash in patients receiving intracoronary stents appears to be underreported.
- Clinical vigilance for cutaneous adverse reactions is warranted in this patient population.
- Further research may be needed to elucidate specific risk factors and optimize antiplatelet strategies.
Abstract:
As many as half of the approximately 400,000 patients who undergo nonsurgical coronary artery procedures every year receive an intracoronary stent. To prevent thrombus formation within the stent, antiplatelet treatment with ticlopidine and aspirin is administered. Ticlopidine is known to cause cutaneous adverse reactions in up to 5.1% of patients, with a 3.4% discontinuation rate. However, published studies of patients receiving the drug to prevent subacute thrombosis after intracoronary stent placement report a frequency of rash ranging from 0.8-1.6%. We hypothesized that the frequency of rash in this patient population is underreported, and conducted a retrospective chart review, collecting data on frequency and severity of rash, treatment required, patient demographics, and concomitant drugs that may predispose patients to rash. The frequency of rash was approximately 7% in this group of patients.